Patients with COVID-19 usually suffer from post-acute sequelae of coronavirus disease 2019 (PASC).

Pulmonary fibrosis (PF) is the most significant long-term effect on patients’ respiratory health.

Risk factors for PASC-induced pulmonary fibrosis include advanced age, chronic comorbidities, the use of mechanical ventilation during the acute phase, and female patients.

The diagnosis of pulmonary fibrosis post-COVID should be based on clinical examination, radiological features, pulmonary function tests, and pathological biomarkers.

The use of antifibrotic treatment for patients with acute respiratory distress syndrome or pneumonia due to COVID-19 might prevent the fibroproliferative process.

Future research is required to have a better understanding of the natural history of pulmonary fibrosis post-COVID, as well as its pathogenesis and clinical and psychosocial impact on patients